Executive Summary
’Personalized Medicine: The impact of proteomics on drug discovery and clinical trial design’ is a management report that analyses how proteomics will streamline drug development and lead to the more cost-effective development of niche personalized products of the future. Proteomics promises lower R&D costs and the opportunities of new revenue streams through the identification of new drug targets in the treatment of diseases such as cancer and Alzheimer’s. Use this report to identify the most important technologies, their applications in drug discovery and clinical trial design and the leading companies driving development of this exciting new area. The pharmaceutical industry has so far been slow to take up proteomic technology and strategic alliances and acquisitions will be central to the pharmaceutical industry’s uptake of proteomics. This report identifies the key technologies that will enable pharmaceutical companies to develop new niche products, improve drug attrition rates, increase the speed of clinical development and target new drug markets.
Other selected research from the 'Proteomics' category:
The Future Of Array Technologies: Impact on drug discovery and market growth in DNA, protein and tissue arrays
Stakeholder Opinions: Diabetic Renal Disease
Other selected research from the 'Drug Discovery' category:
The CRO Market Outlook: Emerging markets, leading players and future trends
Directed Molecular Evolution: Product lifecycle management for biologics